SEC Form 4 at Recursion Pharmaceuticals
Recursion Pharmaceuticals · RXRX · Reported Oct 4, 2024
SEC Form 4 for Recursion Pharmaceuticals (RXRX), reported Oct 4, 2024, explained in plain words next to the official document.
Amount
Filed
Compared with the past
Related filings
The filing, in plain words
One filing, read in full
Every field of the record next to the official document, with how it compares with the past.
Already a member? Sign in
What this page holds
- The filing in plain words
- Context: how it compares with the past
- Related filings at the same company
- A link to the official record
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
Other recent filings by Christopher Gibson, Chief Executive Officer
- SEC Form 4 at Recursion Pharmaceuticals (RXRX)Sep 26, 2025
- SEC Form 4 at Recursion Pharmaceuticals (RXRX)Sep 12, 2025
- SEC Form 4 at Recursion Pharmaceuticals (RXRX)Aug 29, 2025
- SEC Form 4 at Recursion Pharmaceuticals (RXRX)Aug 14, 2025
- SEC Form 4 at Recursion Pharmaceuticals (RXRX)Aug 14, 2025
The full history of Christopher Gibson, Chief Executive Officer is on the profile page.